Amarin Corporation plc
Amarin Corporation plc, often referred to simply as Amarin, is a biopharmaceutical company headquartered in Ireland (IE). Founded in 1989, Amarin has established itself as a leader in the cardiovascular industry, focusing on innovative therapies for the treatment of cardiovascular diseases. The company is best known for its flagship product, Vascepa, a prescription medication that has demonstrated significant efficacy in reducing cardiovascular risk. This unique omega-3 fatty acid formulation sets Amarin apart in a competitive market, addressing unmet medical needs with a strong clinical foundation. With a robust presence in North America and Europe, Amarin continues to expand its reach and influence in the healthcare sector. The company has achieved notable milestones, including regulatory approvals and positive clinical trial results, solidifying its position as a key player in the biopharmaceutical landscape.
DitchCarbon Score
How does Amarin Corporation plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amarin Corporation plc's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amarin Corporation plc's reported carbon emissions
Amarin Corporation plc, headquartered in Ireland (IE), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Amarin may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). As a result, Amarin's climate commitments and emissions profile remain unclear, highlighting a potential area for improvement in transparency and sustainability practices within the pharmaceutical sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Amarin Corporation plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
